Overview

Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer

Status:
Recruiting

Trial end date:
2022-03-30

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of the combination of CPGJ602 and chemotherapy in subjects with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Treatments:

Cetuximab